Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 20 May 2009, doi:10.1136/bmj.b1931
Cite this as: BMJ 2009;338:b1931
| The first 100% of the full text of this article appears below. |
Although proton pump inhibitors reduce the rates of gastrointestinal bleeding in patients with acute coronary syndromes receiving dual antiplatelet treatment,1 recent evidence points to sinister and potentially far more injurious side effects.2 3
Co-prescription of proton pump inhibitors known to inhibit hepatic cytochrome P450 2C19 (omeprazole, lansoprazole, and rabeprazole) with clopidogrel resulted in a 40% relative increase in the risk of recurrent myocardial infarction.2 The risks of rehospitalisation, revascularisation procedures, and death were higher in patients with acute coronary syndromes receiving a proton pump inhibitor and clopidogrel.3 However, pantoprazole and esomeprazole have shown no negative effects on the cardioprotective action of clopidogrel,2 4 probably because of their differing metabolic pathways.5
Not all proton pump inhibitors are born equal, and further studies are urgently required to establish the safest combination.
Cite this as: BMJ 2009;338:b1931
Gareth J Sadler, specialist registrar, gastroenterology1, Andrew P Poullis, consultant gastroenterologist1
1 St Georges Hospital, London SW17
garethsadler@hotmail.com